Antidiabetic drugs and risk of cancer

作者: Anna Tokajuk , Edyta Krzyżanowska-Grycel , Adrian Tokajuk , Sławomir Grycel , Anna Sadowska

DOI: 10.1016/J.PHAREP.2015.05.005

关键词: Diabetes mellitusCohort studyIncidence (epidemiology)PharmacyCancerBioinformaticsAdverse effectPharmacologyInsulinPharmacotherapyMedicine

摘要: Antidiabetic drugs are an important group of medications used worldwide. They differ from each other in the mechanisms lowering blood glucose as well adverse effects that may affect course treatment and its efficacy. In recent years, new have been discovered order to improve maintenance proper level reduce unwanted these drugs. Their growing administration is related increasing incidence diabetes observed all countries world. Epidemiological data indicate increases risk cancer, death linked with neoplasms. It still unknown whether this effect antidiabetic or just itself. years there numerous investigations meta-analyzes, based on both comparative cohort studies trying establish relationship between pharmacotherapy mortality due cancer. According their findings, most increase cancer while only few them show antitumor properties. Different action glucose-lowering be responsible for effects. However, published concerning influence were designed some limitations differed approach. review, we discuss association monotherapy polytherapy risk, consider potential

参考文章(80)
Chung-Wah Wu, Geoffery C Farrell, Jun Yu, Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma Journal of Gastroenterology and Hepatology. ,vol. 27, pp. 1665- 1669 ,(2012) , 10.1111/J.1440-1746.2012.07213.X
Angelo Pietro Femia, Laura Raimondi, Giulia Maglieri, Maura Lodovici, Edoardo Mannucci, Giovanna Caderni, Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. International Journal of Cancer. ,vol. 133, pp. 2498- 2503 ,(2013) , 10.1002/IJC.28260
Emily Jane Gallagher, Derek LeRoith, Diabetes, cancer, and metformin: connections of metabolism and cell proliferation Annals of the New York Academy of Sciences. ,vol. 1243, pp. 54- 68 ,(2011) , 10.1111/J.1749-6632.2011.06285.X
Hannelouise Kissow, Bolette Hartmann, Jens Juul Holst, Niels-Erik Viby, Lærke Schmidt Hansen, Mette Marie Rosenkilde, Kristine Juul Hare, Steen Seier Poulsen, Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regulatory Peptides. ,vol. 179, pp. 91- 100 ,(2012) , 10.1016/J.REGPEP.2012.08.016
Carol Koro, Steven Barrett, Nawab Qizilbash, Cancer risks in thiazolidinedione users compared to other anti‐diabetic agents Pharmacoepidemiology and Drug Safety. ,vol. 16, pp. 485- 492 ,(2007) , 10.1002/PDS.1352
, Basal insulin and cardiovascular and other outcomes in dysglycemia The New England Journal of Medicine. ,vol. 367, pp. 319- 328 ,(2012) , 10.1056/NEJMOA1203858
Shigeru Takeuchi, Toshikatsu Okumura, Wataru Motomura, Miho Nagamine, Nobuhiko Takahashi, Yutaka Kohgo, Troglitazone Induces G1 Arrest by p27Kip1 Induction That Is Mediated by Inhibition of Proteasome in Human Gastric Cancer Cells Japanese Journal of Cancer Research. ,vol. 93, pp. 774- 782 ,(2002) , 10.1111/J.1349-7006.2002.TB01319.X